Explanatory note
(This note is not part of the Order)
This Order further amends the Prescription Only Medicines (Human Use) Order 1997 (“the principal Order”).
Article 2 amends Schedule 1 to the principal Order (which specifies substances which, if included in medicinal products, make them prescription only medicines, and exemptions from the restrictions in section 58(2) on sale and supply of prescription only medicines):
in respect of the entries for Cetirizine Hydrochloride and Loratadine to provide that medicinal products containing these substances may be sold or supplied otherwise than as prescription only medicines without any restriction on the maximum quantity in a container or package;
in respect of the entries for Flurbiprofen and Terbinafine to provide that medicinal products containing these substances may be sold or supplied otherwise than as prescription only medicines on the conditions specified;
to insert an entry for Diphenoxylate Hydrochloride and to provide that medicinal products containing Diphenoxylate Hydrochloride may be sold or supplied otherwise than as a prescription only medicine with Atropine Sulphate on the conditions specified;
to insert entries for the substances Dolasetron Mesilate and Ropinirole Hydrochloride.
An assessment of the cost to business of complying with this Order has been made, copies of which have been placed in the libraries of both Houses of Parliament. Further copies may be obtained from the Department of Health, Medicines Control Agency, Information Centre, Room 10–202, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.